

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Cotadutide (acetate)

Item No. 40714

Svnonvm: MEDI0382

Peptide Sequence: HSQGTFTSD-oxohexadecyl-L-glutamyl-K-SEYLDSERARDFVAWLEAGG-OH

MF: $C_{16}7H_{252}N_{42}O_{55} \bullet C_2H_4O_2$

FW: 3,788.1 **Purity:** ≥95% Supplied as: A solid -20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cotadutide (acetate) is supplied as a solid. A stock solution may be made by dissolving the cotadutide (acetate) in water. Cotadutide (acetate) is slightly soluble (0.1-1 mg/ml) in water. We do not recommend storing the aqueous solution for more than one day.

Description

Cotadutide is a synthetic peptide and dual agonist of the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) that is biased toward GLP-1R.^{1,2} It increases cAMP accumulation in CHO cells overexpressing recombinant human GLP-1R or GCGR (EC $_{50}$ s = 6.9 and 10.2 pM, respectively).¹ It also enhances glucose-stimulated insulin secretion in INS-1 832/3 rat pancreatic β-cells. Cotadutide (10 nmol/kg) reduces food intake and fat mass, as well as improves glucose tolerance in diet-induced obese (DIO) mice. It also reduces food intake and body weight in wild-type but not Glp1r knockout mice, indicating these effects are Glp-1r-dependent, but reduces the hepatic lipid percentage in both wild-type and Glp1r knockout mice, indicating this as a Gcgr-dependent effect.² Cotadutide (10 nmol/kg) reduces total hepatic triglycerides, diglycerides, cholesterol, and free fatty acids, as well as reduces hepatic inflammation and fibrosis, in an ob/ob mouse model of non-alcoholic steatohepatitis (NASH) induced by a high-trans fat, high-fructose, and high-cholesterol diet.

References

- 1. Henderson, S.J., Konkar, A., Hornigold, D.C., et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes. Metab. **18(12)**, 1176-1190 (2016).
- 2. Boland, M.L., Laker, R.C., Mather, K., et al. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat. Metab. 2(5), 413-431 (2020).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 05/02/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM